In vitro and in vivo analysis of B-Myb in basal-like breast cancer
Open Access
- 1 December 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 28 (5), 742-751
- https://doi.org/10.1038/onc.2008.430
Abstract
A defining feature of basal-like breast cancer, a breast cancer subtype with poor clinical prognosis, is the high expression of ‘proliferation signature’ genes. We identified B-Myb, a MYB family transcription factor that is often amplified and overexpressed in many tumor types, as being highly expressed in the proliferation signature. However, the roles of B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly understood. Here, we showed that B-Myb expression is a significant predictor of survival and pathological complete response to neoadjuvant chemotherapy in breast cancer patients. We also identified a significant association between the G/G genotype of a nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-like breast cancer [OR 2.0, 95% CI (1.1–3.8)]. In immortalized, human mammary epithelial cell lines, but not in basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the S427G variant showed increased sensitivity to two DNA topoisomerase IIα inhibitors, but not to other chemotherapeutics. In addition, microarray analyses identified many G2/M genes as being induced in B-Myb overexpressing cells. These results confirm that B-Myb is involved in cell cycle control, and that its dysregulation may contribute to increased sensitivity to a specific class of chemotherapeutic agents. These data provide insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment.This publication has 45 references indexed in Scilit:
- Epidemiology of basal-like breast cancerBreast Cancer Research and Treatment, 2007
- c-Myb is required for progenitor cell homeostasis in colonic cryptsProceedings of the National Academy of Sciences of the United States of America, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- The human synMuv-like protein LIN-9 is required for transcription of G2/M genes and for entry into mitosisThe EMBO Journal, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Common markers of proliferationNature Reviews Cancer, 2006
- An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2005
- E2Fs link the control of G1/S and G2/M transcriptionThe EMBO Journal, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences of the United States of America, 2001